Daiichi Sankyo US
Share
06/16/2026
“If we can help patients, caregivers, and clinicians better understand how our medicines may support a patient’s goals and quality of life, then we are achieving something demonstratively important.”
John and his team know the work doesn’t end once a medicine is approved. Learn how he works to empower patients and caregivers to make the best possible decisions for their individual cancer journey.
📖 Read the full story: https://bit.ly/3QsEnM7
From the Frontlines of 9/11 to Oncology Care From serving at Ground Zero after September 11th to advancing patient-centered oncology care at Daiichi Sankyo, John Ruggiero shares how resilience, compassion, and purpose shaped his journey into the pharmaceutical industry. As Executive Director, U.S. Medical Affairs, HEOR, he reflects on cancer r...
“My mom’s my best friend — she’s truly been my rock.”
For the moms and mother figures — and for everyone shaped by the people who show up for us —
Daiichi Sankyo employees share reflections on inspiration, legacy, and the future they’re working to build.
Together, we’re focused on creating better tomorrows— for one another, for our communities, and for the people we serve.
✨Take a moment to think about someone who’s had a lasting impact on your journey.✨
Nurse ➡️Researcher ➡️Caregiver
Michele Schmidt shares the moment her professional mission became deeply personal - when her father and hero was diagnosed with a rare form of cancer. As a nurse, researcher, and caregiver, Michele reminds us to: keep patients and families at the center, challenge the status quo, and to move with precision when people are waiting for hope.
This isn’t just a career story. It’s a reminder of what’s possible when science is guided by compassion.
📣 Explore more stories of the people behind our science: 🔗 https://bit.ly/4tUqVzk
03/04/2026
Gynecologic cancers are often difficult to detect early — making deeper biological understanding and new treatment approaches critical.
Read how Daiichi Sankyo US is evaluating the potential of HER2-directed therapies in endometrial and ovarian cancers, with a focus on advancing more personalized options for patients.
🔗 https://bit.ly/4bnQLEI
HER2 in Gynecologic Cancers—Why It Matters Gynecologic cancers, cancers that begin in the female reproductive system, remain common and challenging for women. In ovarian cancer, more than 70% of patients with stage 3 to 4 will have a recurrence within five years after diagnosis and treatment decisions become increasingly complex with disease...
Click here to claim your Sponsored Listing.
Category
Contact the practice
Website
Address
211 Mt. Airy Road
Basking Ridge, NJ
07920
